May 28, 2021 – Olympus (Center Valley, PA) has acquired medical device maker Medi-tate (Israel), following the announcement of its decision to exercise the call option in February 2021.
The acquisition will expand Olympus’ business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment.
Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product iTind has received U.S. FDA de Novo authorization and a European CE mark.
With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.
By adding the non-ablative BPH treatment device iTind to its portfolio, Olympus can provide Urologists more treatment options according to the symptoms and needs of their patients, in this case a non-ablative, in-office day treatment.